November 3, 2022 – Luye Pharma Group today announced that Ruoxinlin® (Toludesvenlafaxine Hydrochloride Extended-Release Tablets), its innovative drug for treating Major Depressive Disorder (MDD)...
October 27, 2022 -- Luye Pharma Group announced today that BA2101 has been approved by the Center for Drug Evaluation of the National Medical Products Administration for clinical trials in China. This...
On September 13, 2022, Luye Life Sciences Group and the Ministry of Innovative Development of the Republic of Uzbekistan signed a Memorandum of Understanding (MoU) for strategic collaboration on the U...
Shanghai, September 12, 2022 – BA-CovMab injection, the broad-spectrum neutralizing antibody developed by Luye Pharma Group subsidiary Boan Biotech for use against severe acute respiratory syndr...
Shanghai, September 7, 2022 - Luye Pharma Group announced today that BA1106, a human anti-CD25 monoclonal antibody developed by its subsidiary Boan Biotech, has been approved for clinical trials by th...
August 15, 2022 - Luye Pharma Group today announced that the New Drug Application (NDA) for its Goserelin Acetate Extended-release Microspheres for Injection (LY01005) for the treatment of breast canc...
Shanghai, July 24, 2022 — Luye Pharma Group announced today that its investigational drug Goserelin Acetate Extended-Release Microspheres for Injection (LY01005) for the treatment of breast cancer ha...
July 19, 2022 - Luye Pharma Group announced today that its investigational drug Rotigotine Extended-release Microspheres for Injection (LY03003) has met the expected endpoints in a phase III clinical ...
Shanghai, July 17, 2022 — Luye Pharma Group today announced that Lurbinectedin, an innovative anticancer drug, has been approved by the Hainan Medical Products Administration for urgent clinical use ...
The Phase III clinical trial results of Luye Pharma’s investigational drug LY03005, designated as a “Class 1 Chemical Drug” in China, were presented at the 2022 Annual Meeting of the American ...
TOP